BioNTech SE - ADR Stock News

Bristol-Myers Squibb Co (NYSE: BMY) is inching up on Monday after announcing an $11 billion deal with BioNTech SE (Nasdaq: BNTX) aimed at transforming cancer treatment. The pharmaceutical behemoth announced the said partnership at ASCO, the world's largest cancer conference in Chicago.

BioNTech (BNTX 20.19%), one of the companies made famous for its role developing vaccines with Pfizer (PFE -0.47%) during the COVID-19 pandemic, soared 20.2% through 12:50 p.m. Monday on news entirely unrelated to COVID.

Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug game.

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.

U.S. drugmaker Bristol Myers Squibb announced on Monday a $1.5 billion upfront payment to partner with Germany's BioNTech , on an experimental cancer drug, in a deal that could eventually exceed $11 billion in value for BioNTech.

MAINZ, Germany, and PRINCETON, USA, June 2, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work j...

Biontech US09075V1026 wird die weitere Entwicklung eines seiner vielversprechendsten Wirkstoffkandidaten zur Behandlung von Krebs gemeinsam mit dem US-Konzern Bristol-Myers Squibb US1101221083 vorantreiben.

Eine milliardenschwere Kooperationsvereinbarung hat am Montag den Kurs von Biontech US09075V1026 deutlich belebt.